全文获取类型
收费全文 | 51660篇 |
免费 | 4347篇 |
国内免费 | 1372篇 |
专业分类
耳鼻咽喉 | 300篇 |
儿科学 | 1853篇 |
妇产科学 | 550篇 |
基础医学 | 3508篇 |
口腔科学 | 308篇 |
临床医学 | 6075篇 |
内科学 | 7928篇 |
皮肤病学 | 432篇 |
神经病学 | 1771篇 |
特种医学 | 1393篇 |
外国民族医学 | 9篇 |
外科学 | 14574篇 |
综合类 | 7381篇 |
现状与发展 | 5篇 |
预防医学 | 1991篇 |
眼科学 | 387篇 |
药学 | 4639篇 |
28篇 | |
中国医学 | 2109篇 |
肿瘤学 | 2138篇 |
出版年
2024年 | 84篇 |
2023年 | 844篇 |
2022年 | 1205篇 |
2021年 | 2295篇 |
2020年 | 2068篇 |
2019年 | 1902篇 |
2018年 | 1867篇 |
2017年 | 1857篇 |
2016年 | 2022篇 |
2015年 | 2074篇 |
2014年 | 3492篇 |
2013年 | 4274篇 |
2012年 | 2640篇 |
2011年 | 2867篇 |
2010年 | 2390篇 |
2009年 | 2441篇 |
2008年 | 2423篇 |
2007年 | 2415篇 |
2006年 | 2362篇 |
2005年 | 2111篇 |
2004年 | 1824篇 |
2003年 | 1534篇 |
2002年 | 1292篇 |
2001年 | 1154篇 |
2000年 | 902篇 |
1999年 | 756篇 |
1998年 | 597篇 |
1997年 | 614篇 |
1996年 | 572篇 |
1995年 | 524篇 |
1994年 | 498篇 |
1993年 | 401篇 |
1992年 | 369篇 |
1991年 | 319篇 |
1990年 | 274篇 |
1989年 | 266篇 |
1988年 | 218篇 |
1987年 | 197篇 |
1986年 | 161篇 |
1985年 | 204篇 |
1984年 | 194篇 |
1983年 | 124篇 |
1982年 | 121篇 |
1981年 | 120篇 |
1980年 | 102篇 |
1979年 | 75篇 |
1978年 | 85篇 |
1977年 | 53篇 |
1976年 | 61篇 |
1975年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
141.
Borras Merce; Valdivielso Jose M.; Egido Ramon; Vicente de Vera Pilar; Bordalba Josep Ramon; Fernandez Elvira 《Nephrology, dialysis, transplantation》2006,21(3):789-791
142.
The urinary cyclic AMP response to bovine parathyroid hormone and urinary concentrating ability (max Uosm) after des-amino-D -arginine vasopressin were studies in nine volunteers and seven patients receiving long-term neuroleptic treatment. Max Uosm was lower in the patient group (770 ± 70 mosmol/kg) compared with the controls (948 ± 152 mosmol/kg) but the trend to a lower cAMP response to bovine PTH was not statistically significant. These results suggest that, although adenylate cyclase inhibition may contribute, other mechanisms are also important in the genesis of reduced uring concentrating ability in patients treated with psychotropic drugs. 相似文献
143.
P. Subashini Dr. A. Ravikumar M.S. DNB DLORCS M. S. Ranjit V. K. Sairam R. P. Vatsanath S. Jayasree 《Indian journal of otolaryngology and head and neck surgery》2007,59(1):73-75
A two and half year old male child was seen with systemic hypertension, left ventricular dysfunction, mitral regurgitation and congestive cardiac failure. Examination revealed adenoid hypertrophy. He was also suffering from obstructive sleep apnea. He was being treated with anti-hypertensive and anti-failure drugs. Adenoidectomy was performed following which obstructive sleep apnea symptoms disappeared and his cardiac status improved markedly. Subsequently he was weaned off anti-hypertensive and anti-failure therapy. 相似文献
144.
A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation 总被引:1,自引:0,他引:1
Beckingham I. J.; Woodrow G.; Hinwood M.; Rigg K. M.; Morgan A. G.; Burden R. P.; Broughton-Pipkin F. 《Nephrology, dialysis, transplantation》1995,10(12):2316-2320
BACKGROUND: Erythrocytosis is a common complication of renal transplantationwith an incidence of up to 17%. It is associated with an increasedrisk of complications due to thromboembolic events and has traditionallybeen treated by intermittent venesection. More recently, angiotensin-convertingenzyme inhibitors have been shown to cause a fall in haematocritin a number of groups of subjects and some uncontrolled studieshave shown these drugs to be of possible therapeutic benefitin post renal transplant erythrocytosis. METHODS: We performed a randomized double-blind placebo-controlled studyin 25 patients with post-transplant erythrocytosis. Subjectsreceived either 2.5 mg of enalapril daily or a placebo for 4months and all patients completed the study period without anyserious adverse effects. RESULTS: Haematocrit fell from 52.7 (±SEM 0.7) to 47.1 (±1.8) at 1 month and 46.1 (± 1.2) after 4 months in patientsreceiving enalapril, with no change in the placebo group (P=0.004).We did not demonstrate any change in serum erythropoietin ineither group. CONCLUSION: Angiotensin-converting enzyme inhibitors are a safe and effectiveform of treatment for erythrocytosis developing after renaltransplantation. The mechanism of action, however, is not mediatedby changes in erythropoietin production and remains uncertain. 相似文献
145.
Robert Motzer Howard Scher Dean Bajorin Cora Sternberg George J. Bosl 《Investigational new drugs》1990,8(4):391-392
Summary Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma. 相似文献
146.
Shelley A. Klemm Richard D. Gordon Terry J. Tunny Wendy L. Finn 《Clinical and experimental pharmacology & physiology》1990,17(3):191-195
1. Plasma potassium and chloride concentrations were raised and plasma renin activity, aldosterone, bicarbonate and arterial pH were reduced in two brothers with the syndrome of hypertension and hyperkalaemia with normal glomerular filtration rate (Gordon's syndrome), on unrestricted or moderately restricted sodium diets. 2. These abnormalities were corrected in both patients within 10 days of severe sodium restriction. 3. Pressor sensitivity to cold and angiotensin II decreased on low sodium diet, associated with a fall in blood pressure. 4. Increasing distal tubular sodium delivery by infusion of normal saline increased fractional excretion of potassium when aldosterone had been stimulated by severely restricted sodium diet, but not when aldosterone levels were low on unrestricted sodium diet. 5. These findings are consistent with excessive sodium reabsorption as the primary renal lesion in Gordon's syndrome, leading to volume expansion and suppression of renin and aldosterone. Severe dietary sodium restriction leading to volume contraction, by stimulating renin and aldosterone and promoting kaliuresis, corrects the abnormalities. 相似文献
147.
A. G. Dupont 《European journal of clinical pharmacology》1990,38(Z2):S96-S100
A randomized, double-blind, placebo-controlled study was conducted to study the effects of acute and chronic administration of carvedilol in essential hypertension, with special emphasis on renal haemodynamics and function. Acute administration of a single dose of 50 mg carvedilol reduced systolic and diastolic blood pressure without inducing reflex tachycardia. Renal blood flow was preserved; accordingly, renal vascular resistance was significantly reduced. A significant reduction in the glomerular filtration rate and filtration fraction was observed. Plasma renin activity (PRA) and plasma aldosterone values were not changed. Chronic carvedilol treatment produced a significant fall in systolic and diastolic blood pressure, heart rate, PRA and plasma aldosterone. Renal blood flow, glomerular filtration rate and filtration fraction also remained unchanged; renal vascular resistance decreased significantly. It is concluded that carvedilol possesses definite antihypertensive and renal vasodilating properties, both acutely and after chronic treatment. 相似文献
148.
Metastatic renal cell carcinoma has occasionally been reported to mimic malignant pleural mesothelioma. Morphologically, histochemically and immunohistochemically, similarities in the two tumours exist making their differentiation difficult, particularly in biopsy specimens. The aim of this study was to make a comparative immunohistochemical analysis of the two tumours by use of a panel of four antibodies (Leu M1; Ber EP4; thrombomodulin and Tamm-Horsfall protein). Their suitability in differentiating between the two tumours was assessed. We examined 20 cases of renal cell carcinoma and 20 cases of malignant pleural mesothelioma. On immunostaining with Leu M1, 14 of 20 renal cell carcinomas were positive, yielding 70% sensitivity and 95% specificity and one of 20 mesotheliomas. In comparison, Ber EP4 antibody stained only seven of 20 of the renal cell carcinomas. In addition, it was noted that four tubulopapillary pattern renal cell carcinomas stained positively with both anti-Leu M1 antibody and Ber EP4 antibody. Thrombomodulin immunostaining was present in 11 of 20 mesotheliomas (55% sensitivity and demonstrated 95% specificity) and one of 20 renal cell carcinomas. For epithelial mesotheliomas only, thromobomodulin staining was identified in 10 of 14 cases. In the differentiation of renal cell carcinoma from epithelial mesothelioma we recommend the use of Leu M1 and thrombomodulin as diagnostically useful markers. None of the antibodies used in this study was effective in distinguishing sarcomatoid renal cell carcinoma from sarcomatous mesothelioma. Tamm-Horsfall protein showed little diagnostic utility in differentiating the two tumours. 相似文献
149.
Aims : Adenocarcinomas account for about 60% of metastatic cancers of unknown primary (CUP) site. In such a clinical CUP situation, histopathologists are challenged to differentiate renal cell carcinomas (RCC) from other adenocarcinomas with similar immunophenotypes, especially chemotherapeutically treatable mammary and ovarian carcinomas. Methods and results : Recently, we produced a monoclonal antibody (mAb), designated 138H11, against human gamma-glutamyltransferase (γGT), which stained over 98% primary clear cell and chromophilic RCC on frozen sections. The 138H11 epitope could not be stained using conventional techniques in most paraffin-embedded sections of the same origin, due to destruction by formalin fixation below the detection level. Here, we demonstrate that mAb 138H11 can specifically stain γGT in paraffin-embedded primary and metastatic RCC after enhancement with an ultrasensitive immunohistochemical method. We analysed a selected subgroup of adenocarcinomas with immunophenotypes which would not allow a differentiation from RCC in a CUP situation. We found a predominantly membranous expression of the 138H11 target antigen in 26/51 primary RCC and 15/34 metastatic RCC. In contrast, all 43/43 primary ovarian and bronchial carcinomas as well as 54/54 metastases of ovarian, mammary, bronchial and gastric carcinomas were negative for mAb 138H11. Conclusions : The data suggest that mAb 138H11 is useful for the immunohistochemical differentiation of RCC from other metastatic adenocarcinomas if the primary site of the tumour is not known. 相似文献
150.